bearish
WuXi AppTec (2359.HK/603259.CH) - How Bad Things Could Be?
1.1k Views18 Dec 2023 08:55
We analyzed the growth rate of various business of WuXi AppTec in 2024. Performance will be under pressure if drug R&D demand doesn't pick up in 24H2. It's too early to expect a recovery in 2025
Boomeranged on Wed, 3 Jan 2024 09:20
The share price decline may still be related to concerns about Wuxi AppTec's performance. For example, orders could fall in 23Q4, with no new orders in 24Q1. Some orders could be transferred to India, etc. Geopolitical conflict is another risk, making it harder for Chinese CXOs to be affected by the "dollar tide" as before. Until outlook is clear, investors are advised not to rush to bottom fish.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Pre-IPO Concord Healthcare Group (PHIP Updates) - Some Points Worth the Attention27 Dec 2023
- China Healthcare Weekly (Dec.25) - Stock Picking Strategy, Logic Flaws Behind a Good Story, Tigermed26 Dec 2023
- Pfizer Inc (PFE US) - Continue to Lose Its Way in the Post-Pandemic Era21 Dec 2023
- Wuxi Biologics (2269.HK) - The Business Update Has Torn Away the Last Fig Leaf05 Dec 2023
- WuXi AppTec (2359.HK/603259.CH) 23Q3 - Will the TIDES Business Turn the Tide?02 Nov 2023
- WuXi AppTec (2359.HK/603259.CH) - Would the Recent Rebound in Share Price Be a Flash in the Pan?10 Oct 2023
x